Portfolio

RQ Bio

CEO: Mike Westby, PhD

RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company is advancing its lead product RQB01, a long-acting, potent and broadly protective antibody product, through IND-enabling studies.

Human Health

RQ Bio

RQ Biotechnology Ltd

Scale Space, 58 Wood Lane,

London, W12 7RZ,

United Kingdom.

Industry

Biotech

Year Invested

2026

Status

Current

Location

United Kingdom